Education
About Us
Working with TipRanks
Follow Us
MedinCell SA (FR:MEDCL)
:MEDCL
MEDCL Stock Chart & Stats
€25.18
-€0.24(-1.39%)
At close: 4:00 PM EST
€25.18
-€0.24(-1.39%)
Day’s Range― - ―
52-Week Range€12.00 - €39.68
Previous CloseN/A
Volume18.50K
Average Volume (3M)179.66K
Market Cap
€839.54M
Enterprise Value€0.00
Total Cash (Recent Filing)€53.50M
Total Debt (Recent Filing)€58.27M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Jun 16, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding33,345,783
10 Day Avg. Volume204,359
30 Day Avg. Volume179,664
Financial Highlights & Ratios
PEG Ratio0.80
Price to Book (P/B)-25.60
Price to Sales (P/S)16.41
P/FCF Ratio23.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.30Price Target Upside36.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market DemandMedinCell's partner Teva Pharmaceutical Industries has reported strong market demand for long-acting injectable products, which is a positive indicator for MedinCell.
Market OpportunityBipolar I disorder constitutes a meaningful additional market opportunity, with an estimated 1% of U.S. adults expected to develop the disorder in their lifetime.
Product ApprovalThe FDA has approved UZEDY® as a once-monthly extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.
Bears Say
MedinCell SA News
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €12.00 and its highest was €39.68 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €839.54M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Jun 16, 2026 which is in 177 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Dec 09, 2025. The company reported -€0.18 earnings per share for the quarter, the consensus estimate of -€0.18 by €0.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is 0.01.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 33,345,783 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.18 in its last earnings report, expectations of -€0.18. Following the earnings report the stock price went down -0.75%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in FR:MEDCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell SA (MEDCL) is a biotechnology company that focuses on developing long-acting injectable medications using its proprietary technology platform. The company operates primarily in the pharmaceutical sector, specializing in the formulation and delivery of drugs for various therapeutic areas, including pain management, psychiatry, and contraception. MedinCell's core products include its innovative drug delivery systems that enhance patient compliance and improve treatment outcomes by providing sustained release of active pharmaceutical ingredients over extended periods.
MEDCL Stock 12 Month Forecast
Average Price Target
€34.30
▲(36.22% Upside)
Technical Analysis
Options Prices
Currently, No data available
---